RespiTech successful in securing funding for pulmonary fibrosis research

Novel particulate systems to target pulmonary fibrosis

Novel particulate systems to target pulmonary fibrosis

Members of the RespiTech team and Cell Biology group at the WIMR have been successful in securing an Australia Research Council (ARC) Linkage grant. Chief investigators: Paul Young, Daniela Traini and Brian Oliver have been awarded $370,000 to research and develop a novel anti-fibrotic aerosol.

The research proposal is entitled 'A tight squeeze: engineering anti-fibrotic depot aerosols that circumvent the epithelia'. A new molecule for the treatment of pulmonary lung fibrosis has been developed but there is no inhalation medicine capable of targeting the responsible cells. This project will develop an advanced inhalation technology capable of bypassing the lung surface so that we can target the fibrotic cells beneath. The Project will commence later in 2013  with Australian research partner Pharmaxis Ltd.